| Species |
Cynomolgus |
| Protein Construction |
Kremen-2 (Gly26-Ala364)
Accession # XP_005591068.2 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Kremen-2, His, Cynomolgus at 0.5μg/ml (100μl/well) on the plate can bind AntiKremen2 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
37.04 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Kremen2 (Krm2) plays an important role in embryonic development, bone formation, and tumorigenesis as a crucial regulator of classical Wnt/β-catenin signaling pathway. Compared to para-cancerous tissues, Krm2 was significantly up-regulated in gastric cancer tissues and was positively correlated with the pathological grade of gastric cancer patients. Krm2 can be a potent candidate for designing of targeted therapy. |
| Synonyms |
KRM2; KREMEN2; Kremen-2; Dickkopf receptor 2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
